Similar results have reported a prognostic role for SOX2‐OT in malignant diseases, with a meta‐analysis which indicates that increased SOX2‐OT expression is significantly associated with poor overall survival (OS), and short disease‐free survival (DFS) in osteosarcoma and gastric cancer patients [32]. Here, SOX2 is linked to osteosarcoma.